Deals
Sanofi Said to Be in Advanced Talks to Acquire Actelion
- Companies said to discuss price of about $275 a share
- Deal said possible soon as next week, talks could fall apart
Sanofi Said to Be in Advanced Talks to Acquire Actelion
This article is for subscribers only.
Sanofi is in advanced talks to acquire Actelion Ltd., according to people with knowledge of the matter, in a deal for the Swiss drugmaker that could be announced as soon as next week.
The companies are discussing a price of about $275 per Actelion share, the people said, asking not to be identified because the negotiations are private. That price may include a contingent value right, or CVR, for Actelion shareholders, the people said, which would pay out depending on the future performance of certain pipeline drugs.